Skip to content
Screener

CBRE Group CBRE Deferred and/or contingent consideration

Deferred and/or contingent consideration at other companies

Nano Nuclear Energy logo
Nano Nuclear EnergyNNE
$673.7K+167%
PTH
Pelthos TherapeuticsPTHS
-$1.2M
CareDx logo
CareDxCDNA
$0
Pacira BioSciences, Inc. logo
Pacira BioSciences, Inc.PCRX
$15.79M-10.1%
Amgen logo
AmgenAMGN
$116M+50.6%
Everus Construction Group logo
Everus Construction GroupECG
$4.08M

Other financials

Income statement

See full
Revenue$11.2B+15.1%
Gross profit$2.1B+15.1%
Operating income$365.0M-2.4%
Net income$204.0M-5.1%
EPS (diluted)$0.69-4.2%

Balance sheet

See full
Cash & equivalents$1.5B+6.7%
Total debt$10.7B+11.2%
Total equity$8.4B+1.8%
Total assets$30.5B+10.0%

Cash flow

See full
Operating cash flow-$825.0M-51.1%
CapEx$114.0M+54.1%
Free cash flow-$906.0M-48.5%

Valuation

See full
Market cap$43.77B-5.6%
Enterprise value$53.02B-3.0%
P/E33.7×-8.9×
P/S-0.2×

Profitability

See full
Gross margin18.4%-0.9pp
Operating margin4.5%+0.3pp
Net margin3%+0.1pp
FCF margin2.1%-1.5pp

Returns & leverage

See full
Return on equity15.6%+2.5pp
Debt / equity1.3×+0.1×
Current ratio1.1×0.0×

Where this comes from

Reported directly by CBRE Group in its filing.

Tagged under the XBRL concept cbre:DeferredPurchaseConsideration.

The source filing: CBRE Group’s 10-Q, filed April 23, 2026.

Filed
Apr 23, 2026, 4:39 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001138118-26-000015
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, AT BEGINNING OF PERIOD2,0141,221
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, AT END OF PERIOD$1,795$1,513
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid during the period for:
Interest$98$102
Income tax payments, net$105$131
Non-cash investing and financing activities:
Deferred and/or contingent consideration$(2)$27

Item 1. Financial Statements (Unaudited)

FAQ

What is CBRE Group's deferred and/or contingent consideration?
CBRE Group (CBRE) reported deferred and/or contingent consideration of -$2M in Q1 2026.
How has CBRE Group's deferred and/or contingent consideration changed year-over-year?
CBRE Group's deferred and/or contingent consideration decreased by 107.4% year-over-year, from $27M to -$2M.
What is the long-term trend for CBRE Group's deferred and/or contingent consideration?
Over 4 years (2021 to 2025), CBRE Group's deferred and/or contingent consideration has grown at a -21.6% compound annual growth rate (CAGR), from $485.41M to $183M.
What does deferred and/or contingent consideration mean?
This represents the cash payments made during the period related to the deferred or contingent portion of acquisition prices from past business combinations. These payments are often tied to performance milestones or earn-outs agreed upon at the time of purchase. It helps investors track the long-term cash impact of historical M&A activity.

Ask your AI about CBRE Group's deferred and/or contingent consideration.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude